New support for the Wales & Border Sales
18th July 2025
|
Boehringer Ingelheim is the maker of BULTAVO® 3 and are a leading provider of preventative health solutions for livestock. To date, more than 40 million doses of BULTAVO® 3 have been distributed in Europe to help limit the spread of BTV-3 and its devasting impact. A recent field data published by the German reference laboratory Friedrich-Loeffler-Institut (FLI) showed that vaccination of sheep and cattle with BULTAVO® 3 induces immunity against the virus. According to their findings, animals vaccinated with BULTAVO® 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not.1 BTV-3 causes high mortality in sheep and reproduction and lactation issues in cattle. Outbreaks of Bluetongue can result in severe economic losses for livestock farmers, affect international trade and restrict food supplies. Consequently, the need for effective disease control strategies, including vaccination, remains high. BULTAVO® 3 protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). It is the only BTV-3 vaccine demonstrated to prevent clinical signs and reduce viraemia in sheep, and to prevent clinical signs and viraemia in cattle.
“BULTAVO® 3 plays a vital role in protecting the health of sheep and cattle and safeguarding livelihoods of those who care for them. This vaccine demonstrates our dedication to supporting farmers and authorities in combating BTV-3”, says Findlay MacBean, Head of Livestock at Boehringer Ingelheim Animal Health UK and Ireland. |